Zydus Lifesciences has received approval from China's NMPA for its innovative Desidustat tablets meant for treating renal anaemia. Licensed to a China Medical System subsidiary, the drug addresses ...

New Delhi, Mar 14 (PTI) Zydus Lifesciences on Saturday said its innovative drug has received approval from China’s National Medical Products Administration (NMPA) for its drug Desidustat tablets used ...

In view of strengthening preventive and integrated healthcare care ecosystem, SPARSH Group of Hospitals today announced the launch of a comprehensive Life-Course Vaccination (LCV) Program, ...

Shares of Agenus climbed after the clinical-stage immuno-oncology company triggered the first $20 million contingent payment under its strategic collaboration with Zydus Lifesciences. The stock jumped ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic ...

Feb 25 - Zydus Lifesciences (ZYDU.NS), opens new tab will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in ...

Federal policies under Robert F. Kennedy Jr. that are hostile to vaccines have “sent a chill through the entire industry,” one scientist said. By Rebecca Robbins In Massachusetts, Moderna is pulling ...

Ana Santos Rutschman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...

The Food and Drug Administration has refused to review Moderna's application for its seasonal flu vaccine, the company announced on Feb. 10, marking the latest setback for the development of ...

Feb 12 (Reuters) - India's Zydus Lifesciences (ZYDU.NS), opens new tab and its U.S. unit will pay $120 million to Astellas Pharma (4503.T), opens new tab as part of a deal to settle a patent dispute ...

Feb 12 (Reuters) - India's Zydus Lifesciences and its U.S. unit will pay $120 million ‌to Astellas Pharma as part of ‌a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder ...